Illumina gets funds for bead-based proteomic arrays:
This article was originally published in Clinica
Executive Summary
Illumina has received a $1.2m grant from the US National Institutes of Health to continue its development of high-multiplex, low-cost arrays to profile protein activity in small volumes of cells or biological fluids. Identifying protein profiles will be valuable in a range of markets including diagnostics, said the San Diego, California firm. By profiling and understanding protein activity, pharmaceutical and biotech firms can identify more targeted drug compounds and discover relevant biomarkers for use in diagnostic products. The company added that its proprietary BeadArray technology provided the throughput, cost-effectiveness and flexibility needed to enable researchers to perform the billions of tests necessary to extract medically valuable information from advances in genomics and proteomics.
You may also be interested in...
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.